Ag-Biotech Startup Resurrect Bio Raises $8.1M
What happened
Resurrect Bio, a UK-based agricultural biotechnology startup, has raised $8.1 million in a Series A funding round. The company is developing disease-resistant crops using advanced genome editing techniques, representing growth in applied life sciences beyond human medicine.
Why it matters
- The investment round was led by Corteva Catalyst, the venture capital arm of global agricultural science company Corteva, with participation from investors like Calculus Capital, Pymwymic, and AgFunder. - Resurrect Bio was spun out of The Sainsbury Laboratory, a world-renowned plant science research institute in the UK, and was co-founded by CEO Dr. Cian Duggan, Prof. Tolga Bozkurt, and Prof. Sophien Kamoun. - The company's core technology is a platform named FloraFold®, which uses AI and computational biology to identify and "resurrect" a crop's own suppressed disease resistance genes through precise gene editing. - This approach aims to provide a sustainable alternative to chemical pesticides by restoring a plant's natural ability to fight off threats like fungal diseases, oomycetes, and nematodes. - The company's work exemplifies a key career path in ag-biotech, where bioinformatics scientists and genetic engineers analyze genetic data and modify plant genes, a contrast to patient-facing medical roles. - CEO Dr. Cian Duggan’s career path from a PhD in Plant Molecular Biology to a "scientist-founder" highlights a trajectory in life sciences that combines deep scientific research with entrepreneurship and business development.
Key numbers
- Resurrect Bio, a UK-based agricultural biotechnology startup, has raised $8.1 million in a Series A funding round.
What happens next
- This approach aims to provide a sustainable alternative to chemical pesticides by restoring a plant's natural ability to fight off threats like fungal diseases, oomycetes, and nematodes.
Quick answers
What happened in Ag-Biotech Startup Resurrect Bio Raises $8.1M?
Resurrect Bio, a UK-based agricultural biotechnology startup, has raised $8.1 million in a Series A funding round. The company is developing disease-resistant crops using advanced genome editing techniques, representing growth in applied life sciences beyond human medicine.
Why does Ag-Biotech Startup Resurrect Bio Raises $8.1M matter?
The investment round was led by Corteva Catalyst, the venture capital arm of global agricultural science company Corteva, with participation from investors like Calculus Capital, Pymwymic, and AgFunder. Resurrect Bio was spun out of The Sainsbury Laboratory, a world-renowned plant science research institute in the UK, and was co-founded by CEO Dr. Cian Duggan, Prof. Tolga Bozkurt, and Prof. Sophien Kamoun. The company's core technology is a platform named FloraFold®, which uses AI and computational biology to identify and "resurrect" a crop's own suppressed disease resistance genes through precise gene editing. This approach aims to provide a sustainable alternative to chemical pesticides by restoring a plant's natural ability to fight off threats like fungal diseases, oomycetes, and nematodes. The company's work exemplifies a key career path in ag-biotech, where bioinformatics scientists and genetic engineers analyze genetic data and modify plant genes, a contrast to patient-facing medical roles. CEO Dr. Cian Duggan’s career path from a PhD in Plant Molecular Biology to a "scientist-founder" highlights a trajectory in life sciences that combines deep scientific research with entrepreneurship and business development.
